<SEC-DOCUMENT>0001140361-21-026760.txt : 20210804
<SEC-HEADER>0001140361-21-026760.hdr.sgml : 20210804
<ACCEPTANCE-DATETIME>20210804073029
ACCESSION NUMBER:		0001140361-21-026760
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210804
FILED AS OF DATE:		20210804
DATE AS OF CHANGE:		20210804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BeyondSpring Inc.
		CENTRAL INDEX KEY:			0001677940
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				463009483
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38024
		FILM NUMBER:		211142347

	BUSINESS ADDRESS:	
		STREET 1:		28 LIBERTY STREET
		STREET 2:		39TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10005
		BUSINESS PHONE:		646-528-4184

	MAIL ADDRESS:	
		STREET 1:		28 LIBERTY STREET
		STREET 2:		39TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10005
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>brhc10027570_6k.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">


  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM 6-K</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16</div>
      <div style="text-align: center; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">For the month of August 2021</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Commission File Number: 001-38024</div>
      <div>&#160;</div>
      <div style="text-align: center; font-size: 24pt; font-weight: bold;">BeyondSpring Inc.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">BeyondSpring Inc.</div>
      <div style="text-align: center; font-weight: bold;">28 Liberty Street, 39th Floor</div>
      <div style="text-align: center; font-weight: bold;">New York, New York 10005</div>
      <div style="text-align: center; font-weight: bold;">(Address of principal executive office)</div>
      <div>&#160;</div>
      <div>&#160;</div>
      <div>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
      <div>&#160;</div>
      <div>Form 20-F &#9746; Form 40-F &#9744;</div>
      <div>&#160;</div>
      <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
      <div>&#160;</div>
      <div>Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security
        holders.</div>
      <div>&#160;</div>
      <div>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
      <div>&#160;</div>
      <div>Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant
        foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
        which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already
        been the subject of a Form 6-K submission or other Commission filing on EDGAR.</div>
      <div>&#160;<br>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>On August 4, 2021, BeyondSpring Inc. issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.</div>
      <div>&#160;</div>
      <div>The information contained in this report, except the third, fourth, fifth and sixth paragraphs of Exhibit 99.1, which contain certain quotes by Dr. Feinstein,
        Dr. Sun, Dr. Mohanlal and the Chairperson and Chief Executive Officer of BeyondSpring Inc., is hereby incorporated by reference into the Registration Statements on Form F-3, File No.&#160;333-257639, File No. 333-249816 and File No. 333-234193, and the
        Registration Statements on Form S-8, File No. 333-216639 and File No. 333-240082.</div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div>&#160;</div>
      <div style="text-indent: 36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
        the undersigned, thereunto duly authorized.</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z1361e066bbac45e2a75ab1952d34ee0b" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="3">
              <div>BeyondSpring Inc.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 2%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 38%; vertical-align: top; border-bottom: 2px solid black;">
              <div>/s/ Lan Huang</div>
            </td>
            <td style="width: 10%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="3">
              <div>Name: Lan Huang</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="3">
              <div>Title: Chairperson and Chief Executive Officer</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">&#160;</td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>Date: August 4, 2021</div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 38%; vertical-align: top;">&#160;</td>
            <td style="width: 10%; vertical-align: top;">&#160;</td>
          </tr>

      </table>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="za73d4583a6274fa396c6b5abd2eff45d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 10%; vertical-align: top;">
              <div style="font-weight: bold;"><u>Exhibit No.</u></div>
            </td>
            <td style="width: 90%; vertical-align: top;">
              <div style="text-align: center; font-weight: bold;"><u>Exhibit</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;" rowspan="1">&#160;</td>
            <td style="width: 90%; vertical-align: top;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;">
              <div><a href="brhc10027570_ex99-1.htm">99.1</a></div>
            </td>
            <td style="width: 90%; vertical-align: top;">
              <div>Press release, dated August 4, 2021.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>


</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>brhc10027570_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc
         Document created using EDGARfilings PROfile 8.0.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font></div>
    <div style="text-align: right;"><font style="font-weight: bold;"></font><br>
    </div>
    <div><font style="font-weight: bold;"> </font></div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z887bfff34b85427c961612a1a90dc776">

          <tr>
            <td style="width: 50.00%;" rowspan="1">
              <div style="text-align: right;">&#160;<img src="image00001.jpg"></div>
            </td>
          </tr>

      </table>
      <div style="color: rgb(0, 0, 0); font-weight: bold;"> <br>
      </div>
      <div style="color: rgb(0, 0, 0); font-weight: bold;">BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup>/3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup> Line Non-Small
        Cell Lung Cancer (NSCLC) with EGFR Wild Type</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zd1a5c4474e9d4a93865188db1b556ab4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);"><font style="font-style: italic;">Study met primary endpoint showing statistically significant improvement in overall survival (OS) for the combination vs. docetaxel</font><font style="font-style: italic;">.</font></div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z544064bb300047a089ba8560e152edaf" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-style: italic;">Study met key secondary endpoints showing statistically significant improvement for the combination against docetaxel alone in ORR, PFS, and 24- and 36-month OS rates, and significant
                reduction in incidence of Grade 4 neutropenia.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zc00566355bed49be90573b9f482c1da9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-style: italic;">BeyondSpring plans to seek U.S. FDA and China NMPA approval for plinabulin in combination with docetaxel in NSCLC based on the demonstrated clinical benefit and safety profile.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zaa21463ebb08463ea569b5d0b769265a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-style: italic;">Full data is planned to be presented at upcoming medical conference; The company will host a call at 8:30 a.m. ET today. Dial-in: 877-451-6152, conference ID# 13722298</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div style="color: rgb(0, 0, 0);">NEW YORK, August 4, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the &#8220;Company&#8221; or &#8220;BeyondSpring&#8221;) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, announced today the
        positive topline data of DUBLIN-3 registrational trial in plinabulin in combination with docetaxel to treat 2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup> and 3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup> line NSCLC (EGFR wild type) compared to docetaxel alone (n=559). Plinabulin is a first-in-class, <font style="font-style: italic;">selective immunomodulating microtubule-binding agent</font> (<font style="font-style: italic;">SIMBA</font>), which is a potent antigen presenting cell (APC) inducer. The data released today showed that compared to
        docetaxel alone, the combination met the primary endpoint of increasing overall survival (mean OS, p = 0.03; OS log rank, p &lt;0.04) and met key secondary endpoints, including significantly improving ORR, PFS and 24- and 36-month OS rates, and
        significant reduction in the incidence of Grade 4 neutropenia.</div>
      <div><br>
      </div>
      <div style="color: rgb(0, 0, 0);">The DUBLIN-3 Phase 3 trial is a randomized, single blind to patients, active controlled, global trial that enrolled 559 patients in 2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup> and 3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup> line NSCLC, EGFR wild type, with measurable lung
        lesion. Patients were treated on a 21-day cycle with infusion of docetaxel (75 mg/m<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> on day 1) and plinabulin (30 mg/m<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup> on days 1 and 8) vs. docetaxel alone (75 mg/m<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">2</sup>, day 1). The primary endpoint was overall
        survival.&#160; Plinabulin in combination with docetaxel (DP) showed statistically significant improvements compared to docetaxel alone (D) with topline data summarized below for ITT population (DP: n=278; D: n=281).</div>
      <table cellspacing="0" cellpadding="0" id="z2239f3e42daf4c9d9c516581add2be76" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Primary endpoint (Overall Survival):</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z8525c9f70e1b4713b9dbbde6cf8648df" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">o</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">mean OS: p=0.03; OS log rank: p&lt;0.04<br>
              </div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z76588cfa71bd44fdbbf69f36ac6529f3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Key secondary endpoints:</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z8e57eb62e16548629fc4f0c936b5cda9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">o</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">ORR (p&lt;0.03)</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zdad11c9539e84a71aaa7c6eedda202b2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">o</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">PFS (p&lt;0.01)</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z8088e5d2094b4efbbd254925476ac687" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">o</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Incidence of Grade 4 neutropenia, cycle 1 day 8 (DP: 5.3% vs. D: 27.8%; p&lt;0.0001)</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z453c07f5f47a4aaaad9446ef1473da6d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">o</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">24 Month OS rate (DP: 22.1% vs. D: 12.5%; p &lt;0.01)</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z2f923c5c47564657a0868cec0435327c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">o</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">36 Month OS rate (DP: 11.7% vs. D: 5.3%; p = 0.04)</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="ze3caecb0c2a64f7386f55e9f76fa78d8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">o</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">48 Month OS rate (DP: 10.6% vs. D: 0%; p value cannot be calculated)</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z6c3cba2ead8b46f6861547c8196a02ec" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Safety data:</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="zf7c56067ea8d41d596fdb93da57b7ecf" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">o</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">Lower Grade 4 AE frequency and a shift to lower grade AE</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" id="z9a695c5bec1547aba4a3aacd5e014045" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 54pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0);">o</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0);">No unexpected AE concerns were identified</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 50.00%;" rowspan="1">
                  <div style="text-align: right;">&#160;<img src="image00001.jpg"></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="color: rgb(0, 0, 0);">Trevor M. Feinstein, M.D., of the Piedmont Cancer Institute and a principal investigator for DUBLIN-3 commented, &#8220;The treatment of 2<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup> and 3<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">rd</sup> line NSCLC, especially with EGFR wild type where
        tyrosine kinase inhibitors do not work, is an area of severe unmet medical needs. Now that checkpoint inhibitor immunotherapy has moved into first line, there is a vacuum in this indication, where treatment is heavily centered around docetaxel.
        Currently, docetaxel-based therapies have limited survival benefit and &gt;40% severe neutropenia. In DUBLIN-3, a prolonged survival benefit, characterized by a long-tailed OS curve, was observed with plinabulin that represents an immune associated
        anti-cancer benefit. The opportunity that plinabulin offers to these patients is not only to live longer, but also with significantly reduced severe neutropenia, which are both meaningful for these very sick patients.&#8221;</div>
      <div><br>
      </div>
      <div style="color: rgb(0, 0, 0);">Yan Sun, M.D., co-founder and former Chairman of Chinese Society of Clinical Oncology (CSCO), Chairman of NCCN Guidelines of NSCLC in China, and Director of GCP Center at Cancer Hospital of Chinese Academy of Medical
        Sciences added, &#8220;DUBLIN-3 is a pivotal study which succeeded in demonstrating OS benefit for the first agent with a novel mechanism &#8211; plinabulin &#8211; since the 2015 nivolumab approval. It was very rewarding to be the global Principal Investigator
        throughout the 6 years for the DUBLIN-3 trial that serves to address this severe unmet medical need. In the DUBLIN-3 study, it is especially gratifying to see the doubling of 24- and 36-month OS rate with a favorable safety profile in the
        plinabulin combination arm; this profile not only significantly advances NSCLC patients&#8217; care, but also signals plinabulin&#8217;s profound immune anti-cancer benefit. The success of the DUBLIN-3 study is the gateway of plinabulin into multiple tumor
        indications within IO combinations.&#8221;</div>
      <div>&#160;</div>
      <div style="color: rgb(0, 0, 0);">Dr. Ramon Mohanlal, CMO and EVP of R&amp;D of BeyondSpring said, &#8220;The success of the DUBLIN-3 study represents proof-of-concept of plinabulin&#8217;s immune-enhancing mechanism of action that is complimentary to that of
        checkpoint inhibitors, and which is the rationale for it to be combined as triple IO combinations in multiple tumor indications. These programs are already in Phase 1/2 stage and preliminary positive results were reported at ASCO 2021.&#8221;</div>
      <div><br>
      </div>
      <div style="color: rgb(0, 0, 0);">Dr. Lan Huang, BeyondSpring&#8217;s co-founder, CEO and Chairwoman concluded, &#8220;A pre-NDA meeting will be scheduled with the FDA in 2021 to agree on the contents for our NDA, to support a NSCLC indication NDA submission in
        the first half of 2022. This will be the second indication and second NDA for plinabulin. The superior benefit of plinabulin in reducing severe neutropenia of docetaxel in DUBLIN-3 further supports our first NDA submission in CIN prevention, which
        received FDA priority review with a PDUFA date of November 30, 2021. Importantly, the strong results from DUBLIN-3 further validate our conviction that plinabulin, as an immune anti-cancer agent, has the potential to be a cornerstone therapy for
        many solid tumors. I&#8217;d like to take the time to thank everyone who helped make this 6-year study run smoothly at more than 60 sites across the U.S., China and Australia, including all participating patients and their families, the investigators and
        clinical staff and the dedicated BeyondSpring team.&#8221;</div>
      <div><br>
      </div>
      <div style="color: rgb(0, 0, 0); font-weight: bold;">Conference Call and Webcast Information</div>
      <div><font style="color: rgb(0, 0, 0);">BeyondSpring&#8217;s management will host a conference call and webcast today at 8:30 a.m. Eastern Time. The dial-in numbers for the conference call are 1-877-451-6152 (U.S.) or 1-201-389-0879 (international). Please
          reference conference ID: 13722298. A live webcast will be available on BeyondSpring&#8217;s website at </font><u>www.beyondspringpharma.com</u><font style="color: rgb(0, 0, 0);"> under &#8220;Events &amp; Presentations&#8221; in the Investors section. An archived
          replay of the webcast will be available for 30 days.</font></div>
      <div><font style="color: rgb(0, 0, 0);"> <br>
        </font></div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div style="width: 100%;" id="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 50.00%;" rowspan="1">
                  <div style="text-align: right;">&#160;<img src="image00001.jpg"></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="color: rgb(0, 0, 0); font-weight: bold;">About Plinabulin</div>
      <div style="color: rgb(0, 0, 0);">Plinabulin, BeyondSpring&#8217;s lead asset, is a <font style="font-style: italic;">selective immunomodulating microtubule-binding agent</font> (<font style="font-style: italic;">SIMBA</font>), which is a potent antigen
        presenting cell (APC) inducer. It is a novel, intravenous infused, patent-protected, NDA stage asset for CIN prevention and a Phase 3 anti-cancer candidate for non-small cell lung cancer (NSCLC). Plinabulin triggers the release of the immune
        defense protein, GEF-H1, which leads to two distinct effects: first is a durable anticancer benefit due to the maturation of dendritic cells resulting in the activation of tumor antigen-specific T-cells to target cancer cells, and the second is
        early-onset of action in CIN prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs). Plinabulin received Breakthrough Therapy designation from both U.S. and China FDA for the CIN prevention indication.
        As a &#8220;pipeline in a drug,&#8221; plinabulin is being broadly studied in combination with various immuno-oncology agents that could boost the effects of the PD-1/PD-L1 antibodies and re-sensitize PD-1/PD-L1 antibody-resistant patients.</div>
      <div><br>
      </div>
      <div style="color: rgb(0, 0, 0); font-weight: bold;">About BeyondSpring</div>
      <div style="color: rgb(0, 0, 0);">Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs.
        BeyondSpring&#8217;s first-in-class lead asset plinabulin, is being developed as a &#8220;pipeline in a drug.&#8221; It is filed for approval and has received Priority Review in the U.S. and China for the prevention of chemotherapy-induced neutropenia (CIN) with a
        PDUFA date of November 30, 2021 in the U.S., and has a fully enrolled pivotal study (DUBLIN-3) to test an anti-cancer benefit with an overall survival primary endpoint in NSCLC. Additionally, it is being broadly studied in combination with various
        immuno-oncology regimens that could boost the effects of PD-1 / PD-L1 antibodies. In addition to plinabulin, BeyondSpring&#8217;s extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is
        leveraging a proprietary targeted protein degradation drug discovery platform.</div>
      <div><br>
      </div>
      <div style="color: rgb(0, 0, 0); font-weight: bold;">Cautionary Note Regarding Forward-Looking Statements</div>
      <div style="color: rgb(0, 0, 0);">This press release includes forward-looking statements that are not historical facts. Words such as &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;design,&#8221; &#8220;may,&#8221; &#8220;future,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;objective,&#8221;
        &#8220;goal,&#8221; or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring&#8217;s current knowledge and its present beliefs and
        expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several
        factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company&#8217;s future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in
        regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in
        BeyondSpring&#8217;s most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such
        forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        <div style="width: 100%;" id="DSPFPageHeader">
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;">

              <tr>
                <td style="width: 50.00%;" rowspan="1">
                  <div style="text-align: right;">&#160;<img src="image00001.jpg"></div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div style="color: rgb(0, 0, 0); font-weight: bold;">Investor Contact:</div>
      <div style="color: rgb(0, 0, 0);">Ashley R. Robinson</div>
      <div style="color: rgb(0, 0, 0);">LifeSci Advisors, LLC</div>
      <div style="color: rgb(0, 0, 0);">+1 617-430-7577</div>
      <div style="color: rgb(0, 0, 0);"><u>arr@lifesciadvisors.com</u></div>
      <div><br>
      </div>
      <div style="color: rgb(0, 0, 0); font-weight: bold;">Media Contact:</div>
      <div style="color: rgb(0, 0, 0);">Darren Opland, Ph.D.</div>
      <div style="color: rgb(0, 0, 0);">LifeSci Communications</div>
      <div style="color: rgb(0, 0, 0);">+1 646-627-8387</div>
      <div style="color: rgb(0, 0, 0);"><u>darren@lifescicomms.com</u></div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  [ ,L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZIHHI&8*I
M+$ #J2<4 86H^*+'3M=BTR[#H\BJ1+CY02> :UK>]MKF>>&"9))8"%D53G:?
M0UY_K]M-J'BR%-=M8K6V5ML-U')MW*#D9R>?R&,UH^'K672?%-_;VL1DAN5:
M=KB4XRQ)(1?7'.3_ "KDC6GSM-:7.:-6?-9K2YI:_P"+K+3M+EN+1TNI5E,
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04 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
